Fig. 1.

Percentage of patients with improvement across the musculoskeletal disease activity domain in terms of A arthritis, B enthesitis and dactylitis, C spinal and hip pain assessed using BASDAI item #2 in patients with PsA at week 16 in the FUTURE 2–5 trials. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, LDI Leeds Dactylitis Index, LEI Leeds Enthesitis Index, LSM least squares mean, PsA psoriatic arthritis, SJC swollen joint count, TJC tender joint count, TNF-IR tumor necrosis factor inhibitor inadequate responder. ^†Among patients with enthesitis or dactylitis at baseline only. *P < 0.05 vs placebo